Logo

Agilent Expects 2- to 5-Percent Decline in Q3 Revenue; Closes Stratagene Buy

Jun 07, 2007
NEW YORK (GenomeWeb News) — Agilent Technologies today said it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, or to between $1.38 billion and $1.42 billion from $1.45 billion last year.
 
The company also said it has closed its acquisition of Stratagene for $10.94 a share, or $246 million.
 
Agilent said Stratagene has more than 450 employees, who have now joined the firm. The company did not mention trimming Stratagene’s workforce.
 
Stratagene has operations in Texas, California, Japan, and Amsterdam.
Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.